Status
Conditions
Treatments
About
Minimal hepatic encephalopathy (MHE) is a covert form of hepatic encephalopathy associated with cognitive and psychomotor impairment in patients with compensated liver cirrhosis. Early detection of MHE is crucial to prevent progression to overt encephalopathy. The Psychometric Hepatic Encephalopathy Score (PHES) is a validated neuropsychological test battery for diagnosing MHE. This study aims to screen for MHE among compensated cirrhotic patients using PHES and to compare performance with healthy matched controls.
Full description
This cross-sectional case-control study will include compensated cirrhotic patients aged 18-70 years attending Sohag University Hospital, as well as a control group of healthy volunteers matched for age and education. All participants will undergo clinical evaluation, laboratory investigations, abdominal ultrasound, and psychometric assessment using the PHES battery (NCT-A, NCT-B, DST, SDT, LTT). PHES performance will be compared between cases and controls. The diagnostic accuracy of PHES for detecting MHE will be evaluated using sensitivity, specificity, PPV, NPV, and AUROC. Correlation analyses will explore associations between PHES scores and liver disease severity.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Inclusion Criteria (Cirrhotic Patients):
Age 18-70 years.
Diagnosed compensated liver cirrhosis, regardless of etiology.
Able to read and write.
Adequate vision, hearing, and physical ability to perform the PHES tests.
Inclusion Criteria (Healthy Controls):
Age 18-70 years.
No chronic medical, neurological, psychiatric, renal, or cardiac disease.
Able to read and write.
Adequate cognition, hearing, vision, and physical ability.
Exclusion Criteria:
150 participants in 2 patient groups
Loading...
Central trial contact
Sara Sabry, Resident doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal